WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities

SHANGHAI  -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients (APIs) and GMP intermediates for branded commercial drugs from regulatory agencies in the United States, Canada, the European Union, Switzerland, China, Japan, Australia, and New Zealand.

STA's integrated platform of services, extending from process research to research manufacturing to commercial manufacturing, helps clients move their new chemical entities through preclinical and clinical development to global commercial launch.

"I'm very proud of our track record in securing approvals from global regulatory agencies and the added confidence these successes bring to our partners," said Dr. Minzhang Chen, CEO of STA.

"This favorable outcome further demonstrates that STA's facilities, processes, and people are world-class and of the highest quality," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech.  "We look forward to expanding these capabilities with our new facilities under construction in Changzhou to better serve our partners."

About WuXi PharmaTech

WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge (for investors) 
LaVoieHealthScience 
+1-617-374-8800 x109 
+1 617-792-2459 
[email protected]

Aaron Shi (for the media) 
Director, Corporate Communications  
WuXi PharmaTech 
+86-21-5046-4362 
[email protected]

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.